Drug Shortages

ASCO members should have received an invitation on March 16 to participate in an oncology drug shortages survey to help ASCO and its membership understand the impact of drug shortages.

[Read the rest of this article...]

Janssen Products, LP is releasing another lot of DOXIL® (doxorubicin HCl liposome injection) for physicians and their patients, under the regulatory discretion of the U.S. Food and Drug Administration (FDA).

[Read the rest of this article...]

U.S. Representative John Carney [D-Del.] was recognized at a February 21 event by ASCO and its state affiliate the Delaware Society for Clinical Oncology (DSCO) for his continued support and leadership at the state and federal levels in Delaware’s fight against cancer.  The reception included remarks by ASCO President Sandra M. Swain, MD, and DCSO President Jon Strasser, MD. The event was held at the Medical Society of Delaware.

[Read the rest of this article...]

The U.S. Food and Drug Administration approved doxorubicin hydrochloride liposome injection (Sun Pharma Global FZE), a generic version of DOXIL Injection (doxorubicin hydrochloride liposome; Janssen Products, L.P.) for the treatment of ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy and for AIDS-related Kaposi's sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy.

[Read the rest of this article...]

Janssen Products, LP, has announced that it is coordinating with the Food and Drug Administration to create additional supply of DOXIL using an alternative manufacturing process.

[Read the rest of this article...]

ASCO Immediate Past President Michael P. Link, MD, recently co-authored a perspectives piece in The New England Journal of Medicine on the impact of using drug shortages on children with cancer.

[Read the rest of this article...]

ASCO members should have received ASCO’s national survey on the impact of oncology drug shortages on their practice by email on October 6. This questionnaire is intended to help ASCO and its membership understand the impact of legislative and administrative efforts to mitigate drug shortages. 

[Read the rest of this article...]

Janssen Products, LP, has announced that it has restored full access to DOXIL® (doxorubicin HCl liposome injection) for physicians and the patients they serve. 

[Read the rest of this article...]